(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.31%) $82.75
(6.34%) $2.05
(0.06%) $2 348.50
(-0.30%) $27.45
(4.14%) $960.30
(-0.21%) $0.933
(-0.36%) $10.98
(-0.53%) $0.796
(1.66%) $93.40
0.03% INR 346.05
Live Chart Being Loaded With Signals
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally...
Stats | |
---|---|
Dagens volum | 856 777 |
Gjennomsnittsvolum | 2.11M |
Markedsverdi | 0.00 |
EPS | INR4.77 ( 2021-12-30 ) |
Last Dividend | INR3.50 ( 2021-07-29 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 7.43 |
ATR14 | INR0 (0.00%) |
Zydus Lifesciences Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
BCG.NS | 0.954 |
TIDEWATER.NS | 0.948 |
TATVA.NS | 0.941 |
SINTEX.NS | 0.933 |
CLNINDIA.NS | 0.932 |
BUTTERFLY.NS | 0.932 |
INDLMETER.NS | 0.93 |
GILLETTE.NS | 0.929 |
DBL.NS | 0.927 |
AMBICAAGAR.NS | 0.925 |
10 Mest negative korrelasjoner | |
---|---|
MUKANDENGG.NS | -0.954 |
JBMA.NS | -0.945 |
KIRLOSIND.NS | -0.939 |
GFSTEELS.NS | -0.937 |
FINCABLES.NS | -0.92 |
FOCUS.NS | -0.919 |
KEERTI.NS | -0.917 |
STAMPEDE.NS | -0.914 |
JSLHISAR.NS | -0.914 |
LINDEINDIA.NS | -0.913 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Zydus Lifesciences Økonomi
Annual | 2022 |
Omsetning: | INR170.51B |
Bruttogevinst: | INR68.01B (39.89 %) |
EPS: | INR19.30 |
FY | 2022 |
Omsetning: | INR170.51B |
Bruttogevinst: | INR68.01B (39.89 %) |
EPS: | INR19.30 |
FY | 2021 |
Omsetning: | INR148.22B |
Bruttogevinst: | INR93.42B (63.03 %) |
EPS: | INR20.84 |
FY | 2020 |
Omsetning: | INR138.12B |
Bruttogevinst: | INR86.63B (62.72 %) |
EPS: | INR11.49 |
Financial Reports:
No articles found.
Zydus Lifesciences Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR0.200 | 2000-05-02 |
Last Dividend | INR3.50 | 2021-07-29 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 22 | -- |
Total Paid Out | INR96.45 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 1.87 | -- |
Div. Sustainability Score | 4.12 | |
Div.Growth Potential Score | 3.01 | |
Div. Directional Score | 3.57 | -- |
Year | Amount | Yield |
---|---|---|
2000 | INR0 | 0.00% |
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR3.50 | 0.90% |
2019 | INR3.50 | 1.00% |
2020 | INR3.50 | 1.38% |
2021 | INR3.50 | 0.73% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TNPETRO.NS | Dividend Junior | 2023-09-18 | Sporadic | 23 | 2.02% | |
PFIZER.NS | Dividend Junior | 2023-08-11 | Annually | 22 | 0.82% | |
JAYBARMARU.NS | Dividend Junior | 2023-09-08 | Annually | 23 | 1.48% | |
DCMSHRIRAM.NS | Dividend Junior | 2023-07-18 | Semi-Annually | 23 | 1.23% | |
SIYSIL.NS | Dividend Junior | 2023-07-24 | Semi-Annually | 18 | 1.37% | |
MEDICAMEQ.NS | Ex Dividend Junior | 2023-09-20 | Annually | 3 | 0.02% | |
GULFOILLUB.NS | Dividend Junior | 2023-08-25 | Annually | 11 | 2.19% | |
BBTC.NS | Dividend Junior | 2023-09-22 | Annually | 22 | 0.08% | |
PRESTIGE.NS | Dividend Junior | 2023-09-14 | Annually | 14 | 0.25% | |
KANSAINER.NS | Dividend Junior | 2023-05-25 | Annually | 21 | 0.49% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.156 | 1.500 | 6.87 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.328 | 1.500 | 7.46 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 57.27 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 14.57 | 2.00 | 5.14 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 14.57 | 2.00 | 2.71 | 5.43 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.470 | 1.000 | 5.49 | 5.49 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.224 | 1.000 | 7.53 | 7.53 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.78 | 1.000 | 8.91 | 0 | [1 - 100] |
returnOnEquityTTM | 0.328 | 2.50 | 8.37 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 14.57 | 2.00 | 5.14 | 5.43 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 14.57 | 2.00 | 5.14 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.324 | 1.500 | -5.49 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0775 | 1.000 | -0.562 | 0 | [0.1 - 0.5] |
Total Score | 3.01 |
Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.